Immunohistological analysis of representative tumor sections from the control and GA-amide-treated tumors at the endpoint showed decreased expression of Ki67 and the GSC marker prominin 1 (CD133) as well as an increased level of cleaved caspase3 in GA-amide-treated tumors (Supplementary Fig. 2), suggesting that GA-amide inhibited glioma in vivo. This evidence concerns the gene MKI67 and central nervous system cancer.